Kamada announces financial results for the three and nine months ended September 30, 2014 and affirms 2014 revenue guidance.
Kamada management will host an investment community conference call on Wednesday, November 12, 2014 at 8:30 a.m. Eastern time to discuss these results and answer questions.
Orphan drug designation carries multiple benefits, including the availability of grant money, certain tax credits and seven years of market exclusivity, as well as the possibility of an expedited regulatory process.
(Bloomberg) — David Tsur, chief executive officer at Kamada, talks with Elliott Gotkine about what comes next for the company. He speaks on “The Pulse".
Anti-inflammatory activity of AAT may modulate immune system to prevent it from attacking pancreatic beta cells
Increases minimum Glassia sales through 2017 to a total of over $190 million since 2010
Conference call with Kamada management and clinical trial investigators to be held today at 8:00 a.m. Eastern time. Shareholders and other interested parties may participate in the call by dialing (888) 803-5993 (domestic), (1-809) 45-7877 (from Israel) or (706) 634-5454 (international) and referencing conference ID number 95044902.
Kamada announces financial results for the three and six months ended June 30, 2014.
Kamada management will host an investment community conference call today beginning at 8:30 a.m. Eastern time to discuss these results and answer questions. To participate in the conference call, please find dialing details below.
Kamada management will host an investment community conference call on Thursday, August 14, 2014 beginning at 8:30 a.m. Eastern time
Positive clinically meaningful efficacy signs in the inhaled AAT group including an approximate 50% reduction in severe exacerbation rates versus placebo
Continues with plans to submit for licensure in Europe in Q4 2014
Conference call begins at 8:30 a.m. Eastern time